Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MBRX Moleculin Biotech	$0.57 -4.9%	$0.57	$0.25 ▼ $3.65	$17.19M	1.39	4.40 million shs	1.94 million shs
RLMD Relmada Therapeutics	$0.63 +2.8%	$0.63	$0.24 ▼ $3.98	$20.81M	0.66	1.13 million shs	98,594 shs
SNOA Sonoma Pharmaceuticals	$5.09 +0.6%	$3.42	$1.75 ▼ $6.92	$8.36M	1.25	1.55 million shs	156,905 shs
TRIB Trinity Biotech	$1.57 +0.6%	$0.84	$0.48 ▼ $3.44	$28.34M	0.77	2.85 million shs	819,913 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MBRX Moleculin Biotech	+6.46%	-7.89%	-23.07%	-37.26%	-76.55%
RLMD Relmada Therapeutics	-0.41%	+0.46%	-2.48%	-4.60%	-78.21%
SNOA Sonoma Pharmaceuticals	-0.59%	-3.98%	+42.13%	+57.63%	+2,178.25%
TRIB Trinity Biotech	-10.34%	-18.32%	+116.67%	+125.11%	-29.89%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
MBRX Moleculin Biotech	2.9185 of 5 stars	3.5	4.0	0.0	0.0	1.8	1.7	0.6
RLMD Relmada Therapeutics	4.3449 of 5 stars	3.1	5.0	0.0	4.4	1.1	2.5	0.6
SNOA Sonoma Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TRIB Trinity Biotech	1.526 of 5 stars	0.0	4.0	0.0	0.0	3.1	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MBRX Moleculin Biotech	3.00	Buy	$4.00	604.72% Upside
RLMD Relmada Therapeutics	2.25	Hold	$5.00	697.45% Upside
SNOA Sonoma Pharmaceuticals	0.00	N/A	N/A	N/A
TRIB Trinity Biotech	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest SNOA, MBRX, RLMD, and TRIB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2025	TRIB Trinity Biotech	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/18/2025	MBRX Moleculin Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
6/9/2025	MBRX Moleculin Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$4.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MBRX Moleculin Biotech	N/A	N/A	N/A	N/A	($0.24) per share	N/A
RLMD Relmada Therapeutics	N/A	N/A	N/A	N/A	$0.48 per share	N/A
SNOA Sonoma Pharmaceuticals	$14.91M	0.56	N/A	N/A	$2.47 per share	2.06
TRIB Trinity Biotech	$61.56M	0.46	N/A	N/A	($1.95) per share	-0.81

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MBRX Moleculin Biotech	-$21.76M	N/A	0.00	N/A	N/A	N/A	-1,498.41%	-114.47%	N/A
RLMD Relmada Therapeutics	-$79.98M	-$2.22	N/A	N/A	N/A	N/A	-223.17%	-180.41%	11/6/2025 (Estimated)
SNOA Sonoma Pharmaceuticals	-$3.46M	-$2.46	N/A	N/A	N/A	-23.87%	-50.00%	-16.79%	11/6/2025 (Estimated)
TRIB Trinity Biotech	-$31.79M	-$2.93	N/A	N/A	N/A	-68.48%	N/A	-32.33%	8/27/2025 (Estimated)

Latest SNOA, MBRX, RLMD, and TRIB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/27/2025	Q1 2025	TRIB Trinity Biotech	-$0.51	N/A	N/A	N/A	$16.00 million	N/A
8/12/2025	Q2 2025	MBRX Moleculin Biotech	-$0.39	-$0.49	-$0.10	-$0.49	N/A	N/A
8/7/2025	Q2 2025	RLMD Relmada Therapeutics	-$0.25	-$0.30	-$0.05	-$0.30	N/A	N/A
8/7/2025	Q1 2026	SNOA Sonoma Pharmaceuticals	-$0.51	-$0.37	+$0.14	-$0.76	$4.26 million	$4.01 million
6/17/2025	Q4 2025	SNOA Sonoma Pharmaceuticals	-$0.73	-$0.15	+$0.58	-$0.48	$4.44 million	$3.75 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
MBRX Moleculin Biotech	N/A	N/A	N/A	N/A	N/A
RLMD Relmada Therapeutics	N/A	N/A	N/A	N/A	N/A
SNOA Sonoma Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TRIB Trinity Biotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MBRX Moleculin Biotech	N/A	1.15	1.15
RLMD Relmada Therapeutics	N/A	4.11	4.11
SNOA Sonoma Pharmaceuticals	N/A	2.70	1.92
TRIB Trinity Biotech	N/A	1.17	0.50

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MBRX Moleculin Biotech	15.52%
RLMD Relmada Therapeutics	45.24%
SNOA Sonoma Pharmaceuticals	1.95%
TRIB Trinity Biotech	78.97%

Insider Ownership

Company	Insider Ownership
MBRX Moleculin Biotech	2.10%
RLMD Relmada Therapeutics	20.70%
SNOA Sonoma Pharmaceuticals	24.59%
TRIB Trinity Biotech	8.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MBRX Moleculin Biotech	20	30.29 million	29.65 million	Not Optionable
RLMD Relmada Therapeutics	10	33.19 million	26.32 million	Optionable
SNOA Sonoma Pharmaceuticals	180	1.64 million	1.24 million	Not Optionable
TRIB Trinity Biotech	480	18.05 million	16.57 million	Optionable

SNOA, MBRX, RLMD, and TRIB Headlines

Recent News About These Companies

Trinity Biotech Appoints Paul Tivnan as Non-Executive Director

August 21 at 9:00 AM | globenewswire.com

Regulatory Approval Granted for Commencement of Trinity Biotech’s Offshored and Outsourced Manufacturing of its Flagship Rapid HIV Test, Facilitating Strategic and Financial ...

August 21 at 7:52 AM | finance.yahoo.com

Trinity granted approval for offshore manufacturing of TrinScreen HIV test

August 20 at 4:19 PM | msn.com

Regulatory Approval Granted for Commencement of Trinity Biotech's Offshored and Outsourced Manufacturing of its Flagship Rapid HIV Test, Facilitating Strategic and Financial Performance Transformation

August 20 at 9:00 AM | globenewswire.com

Trinity Biotech Launches FDA-cleared Preeclampsia Testing Service

August 19 at 9:29 PM | theglobeandmail.com

Biotech Stocks To Watch Now - August 14th

August 16, 2025 | americanbankingnews.com

Trinity Biotech's Redesigned CGM Sensor Favored by New Clinical Data

August 15, 2025 | zacks.com

Trinity Biotech ADRs Soar on NY Regulator Approval for Preeclampsia Test

August 14, 2025 | marketwatch.com

Trinity Biotech stock soars after NY regulatory approval for preeclampsia test

August 14, 2025 | investing.com

Trinity Biotech receives approval from NYSDOH to provide PreClara Ratio

August 14, 2025 | msn.com

Trinity Biotech Receives Regulatory Approval to Begin FDA-Cleared PreClara™ Preeclampsia Testing Service

August 14, 2025 | globenewswire.com

Trinity Biotech plc: Trinity Biotech Achieves Breakthrough Clinical Trial Results for Redesigned CGM Sensor

August 12, 2025 | finanznachrichten.de

Trinity Biotech announces clinical trial results for redesigned CGM sensor

August 12, 2025 | msn.com

Trinity Biotech reports its 15-day CGM works without fingersticks

August 12, 2025 | fiercebiotech.comF

Trinity Biotech reports positive outcomes with next-gen CGM sensor

August 12, 2025 | drugdeliverybusiness.comD

Trinity Biotech stock rises on successful CGM calibration-free trial

August 12, 2025 | au.investing.com

Trinity Biotech Achieves Breakthrough Clinical Trial Results for Redesigned CGM Sensor

August 12, 2025 | globenewswire.com

Trinity Biotech Announces Launch of FDA-cleared Preeclampsia Testing Service

August 7, 2025 | globenewswire.com

Trinity unveils AI-powered CGM+ biosensor

July 29, 2025 | bioworld.comB

Trinity Biotech outlines plans for wearable CGM+ biosensor platform

July 25, 2025 | fiercebiotech.comF

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNOA, MBRX, RLMD, and TRIB Company Descriptions

Moleculin Biotech NASDAQ:MBRX

$0.57 -0.03 (-4.88%)

Closing price 04:00 PM Eastern

Extended Trading

$0.57 0.00 (-0.11%)

As of 07:09 PM Eastern

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Relmada Therapeutics NASDAQ:RLMD

$0.63 +0.02 (+2.79%)

Closing price 04:00 PM Eastern

Extended Trading

$0.63 0.00 (0.00%)

As of 06:12 PM Eastern

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

Sonoma Pharmaceuticals NASDAQ:SNOA

$5.09 +0.03 (+0.59%)

Closing price 04:00 PM Eastern

Extended Trading

$5.04 -0.04 (-0.88%)

As of 07:12 PM Eastern

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.

Trinity Biotech NASDAQ:TRIB

$1.57 +0.01 (+0.64%)

Closing price 04:00 PM Eastern

Extended Trading

$1.53 -0.04 (-2.55%)

As of 07:04 PM Eastern

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. The company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time